Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Financials
52W LOW $39.1852W HIGH $52.68
Volume
135.87 K
Value Traded
146.12 M
Short % Float
0.39%
+0.78%Week
-6.11%1 Month
-7.52%3 Month
-13.96%6 Month
-17.69%5 Year
+45.21%All Time
Cash Data
- Cash FlowProfitable
- SEC Filing
Key Stats
Market Cap
97.20 B
EPS (TTM)
2.40
P/E Ratio
16.78
Ent. Value
122.63 B
Total Shares
2.42 B
Float Shares
2.38 B
Insiders
0.00%
Institutions
7.98%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
SNY Catalyst Timeline
Dated clinical, regulatory and corporate events for Sanofi
Catalyst Timeline
Dated clinical, regulatory & corporate events for Sanofi
1470Total events
21Upcoming
782Tier-1 (high impact)
2010 to 2027Coverage
Upcoming catalysts 2
Event history 50
▲Partnership / LicenseCorporate
Sanofi and Regeneron expand global antibody collaboration adding four long-acting antibodies
▲Legal / SettlementCorporate
Sanofi and Regeneron settle prior collaboration-related litigation
▲Partnership / LicenseCorporate
Sanofi and Cheplapharm announce intention to create strategic partnership for 20 mature medicines and three manufacturing sites
▲EU ApprovalMenQuadfiApprovedEx-US Regulatory
EC approved extension of indication for MenQuadfi to include infants from six weeks of age
invasive meningococcal diseasesource ↗
▲Full ResultsMenQuadfiApprovedClinical Data
MET58 pivotal study data supporting EU approval
invasive meningococcal diseasesource ↗
▲Pediatric Exclusivity GrantedMenQuadfiApprovedFDA Decision
Paediatric Investigation Plan compliance statement received from EMA
invasive meningococcal diseasesource ↗
▼Program DiscontinuationAmlitelimabDiscontinuedCorporate
Discontinuation of clinical development of amlitelimab in atopic dermatitis; decision not to submit for global regulatory reviews
moderate-to-severe atopic dermatitissource ↗
▼Trial DiscontinuedAmlitelimabDiscontinuedTrial
Wind-down of ongoing amlitelimab AD studies including ESTUARY
moderate-to-severe atopic dermatitissource ↗
▲Partnership / LicenseCorporate
Aqemia and Sanofi expand research collaboration with new target nomination and additional payment
▲FDA ApprovalFDA Decision
FDA approval of subcutaneous Sarclisa Escena for multiple myeloma across all existing IV indications
multiple myelomasource ↗
▲Full ResultsClinical Data
IRAKLIA phase 3 results: non-inferiority of SC Sarclisa Escena via OBI vs IV in combination with Pd
relapsed or refractory multiple myelomasource ↗
◆NDA SubmissionRegulatory Filing
Regulatory submission for CirCLIQ OBI in Japan under review
multiple myelomasource ↗
●FDA Filing AcceptedRegulatory Filing
Regulatory submission for CirCLIQ OBI in Japan under review
multiple myelomasource ↗
▲Topline ReadoutClinical Data
IRAKLIA phase 3 topline results: non-inferiority of SC vs IV Sarclisa
relapsed or refractory multiple myelomasource ↗
▲Primary Endpoint MetNexviazymeApprovedClinical Data
Nexviazyme met primary endpoint in Baby-COMET study
infantile-onset Pompe diseasesource ↗
▲Secondary Endpoint DataNexviazymeApprovedClinical Data
All secondary endpoints met in Baby-COMET study
infantile-onset Pompe diseasesource ↗
▲CHMP Positive OpinionMenQuadfiApprovedEx-US Regulatory
CHMP adopted positive opinion for MenQuadfi infant indication
invasive meningococcal diseasesource ↗
▲Partnership / LicenseCorporate
Sanofi signs MoU with Abu Dhabi Department of Health to explore vaccine innovation center
▲EU ApprovalCenrifkiApprovedEx-US Regulatory
European Commission approval of Cenrifki for SPMS without relapses
secondary progressive multiple sclerosis without relapsessource ↗
▲CHMP Positive OpinionCenrifkiApprovedEx-US Regulatory
CHMP positive opinion for Cenrifki
secondary progressive multiple sclerosis without relapsessource ↗
▲Topline ReadoutTolebrutinibApprovedClinical Data
HERCULES phase 3 topline results supporting approval
non-relapsing secondary progressive multiple sclerosissource ↗
▲Other Regulator MilestoneWayrilzApprovedEx-US Regulatory
Wayrilz approved in Japan for ITP
immune thrombocytopeniasource ↗
▲Other Regulator MilestoneSarclisaApprovedEx-US Regulatory
Sarclisa SC approved in Japan for multiple myeloma
multiple myelomasource ↗
▲Topline ReadoutSarclisaApprovedClinical Data
IRAKLIA topline results: non-inferior efficacy and PK for SC vs IV
relapsed or refractory multiple myelomasource ↗
◆FDA Filing AcceptedSarclisaApprovedRegulatory Filing
Sarclisa SC regulatory submission under review in US
multiple myelomasource ↗
▲EU ApprovalSarclisaApprovedEx-US Regulatory
Sarclisa SC approved in EU for multiple myeloma
multiple myelomasource ↗
▲FDA Filing AcceptedvenglustatFiledRegulatory Filing
FDA accepted NDA for priority review for venglustat in GD3
type 3 Gaucher diseasesource ↗
▲Priority ReviewvenglustatFiledRegulatory Filing
FDA granted priority review for venglustat NDA
type 3 Gaucher diseasesource ↗
▲Topline Readoutefdoralprin alfaClinical Data
Phase 2 ElevAATe topline data demonstrate superiority of efdoralprin alfa over standard-of-care in achieving higher fAAT levels
alpha-1 antitrypsin deficiency (AATD)-related emphysemasource ↗
▲Oral Presentationefdoralprin alfaPresentation
Oral presentation of ElevAATe phase 2 results at ATS 2026
alpha-1 antitrypsin deficiency (AATD)-related emphysemasource ↗
◆Management ChangeCorporate
Belén Garijo appointed as Director and CEO of Sanofi, effective May 1, 2026
●Management ChangeCorporate
Christel Heydemann appointed as independent board member; Frédéric Oudéa appointed Chairman of Appointments Committee
▲Oral PresentationNUVAXOVIDApprovedPresentation
COMPARE study results presented at ESCMID Global Congress
COVID-19source ↗
▲Primary Endpoint MetNUVAXOVIDApprovedClinical Data
COMPARE study met primary endpoint of systemic reactogenicity within 7 days
COVID-19source ↗
▲Primary Endpoint MetLunsekimigClinical Data
DUET phase 2a met primary and key secondary endpoints in CRSwNP
chronic rhinosinusitis with nasal polyps (CRSwNP)source ↗
▼Primary Endpoint MissedLunsekimigClinical Data
VELVET phase 2b did not meet primary endpoint in atopic dermatitis
moderate-to-severe atopic dermatitissource ↗
◆Topline ReadoutAmlitelimabDiscontinuedClinical Data
Phase 2 topline readout in celiac disease expected
celiac diseasesource ↗
▲Late-BreakerAmlitelimabDiscontinuedPresentation
Late-breaking presentation of COAST 2 results at AAD 2026
moderate-to-severe atopic dermatitissource ↗
●Oral PresentationAmlitelimabDiscontinuedPresentation
Previously presented KS case from ATLANTIS at Winter Clinical Miami
moderate-to-severe atopic dermatitissource ↗
▼Safety Data UpdateAmlitelimabDiscontinuedClinical Data
Second KS case identified in blinded ESTUARY study
moderate-to-severe atopic dermatitissource ↗
▲Other Regulator MilestoneDupilumabApprovedEx-US Regulatory
Dupixent approved in Japan for moderate-to-severe bullous pemphigoid
bullous pemphigoidsource ↗
▲Breakthrough Therapy DesignationvenglustatFiledDesignation
FDA granted Breakthrough Therapy designation for venglustat in GD3
type 3 Gaucher diseasesource ↗
▲Other Regulator MilestonerilzabrutinibApprovedEx-US Regulatory
Orphan drug designation granted by MHLW in Japan for IgG4-RD
IgG4-related diseasesource ↗
▲FDA ApprovalDupilumabApprovedFDA Decision
FDA approval for allergic fungal rhinosinusitis in adults and children aged 6 years and older
allergic fungal rhinosinusitissource ↗
Past FDA Catalysts and PDUFA Decisions
How SNY actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-07-09 | Sarclisa Escena (isatuximab-irfc) | PDUFA Date Approved | PDUFA |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
A83 / 100
Pipeline Score
$79.8B
Pipeline Value
$226.7B
Commercial Value
Undervalued
Valuation Signal
164
Drugs Scored
2.7x
rNPV / MCap
Top 2%
Large Pharma(rank 14 of 658)
Percentile Rank
Sanofi earns an A-grade pipeline score (83/100), with $79.9B risk-adjusted pipeline value, led by HOE901-U300 in Type 2 Diabetes Mellitus (Phase 3).
Commercial products (revenue basis: trailing 4 quarters of total revenue (20-F and 6-K), converted from EUR to USD, to Jun 2026; product lines: last four quarters to Jun 2026 (20-F and 6-K)) Revenue $53.5B x 4.2 = $226.7B
| Product | Revenue | Prior period | Change |
|---|---|---|---|
| Dupixent | $20.7B | $16.6B | +24.4% |
| Polio Pertussis Hib Primary Vaccines And Boosters, incl. Heplisav-B | $3.0B | $3.2B | -7.2% |
| COVID-19 and Influenza vaccines | $2.6B | $3.0B | -13.9% |
| RSV vaccines (Beyfortus) | $2.1B | $2.1B | -1.4% |
| Lantus | $1.9B | $2.0B | -4.3% |
| Toujeo | $1.6B | $1.5B | +7.6% |
| ALTUVIIIO | $1.5B | $1.1B | +36.9% |
| Meningitis, travel, and endemic vaccines | $1.4B | $1.6B | -7.4% |
| Fabrazyme | $1.2B | - | - |
| Plavix | $1.0B | - | - |
| Nexviazyme/Nexviadyme | $967M | $856M | +12.9% |
| Lovenox | $862M | $1.1B | -18.9% |
Top 12 of 34 product lines shown.
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|
Clinical Trial Results
Readouts, endpoints and source filings for every SNY program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| efdoralprin alfa Fast TrackOrphan | AATD-related emphysema | Phase 2 | 2026-05-18 | mean increases in fAAT trough levels more than three times greater than plasma-derived protein (pdAAT) dosed weekly (Q1W); p<0.0001; fAAT levels remained above the normal threshold (23.8 M) for 100% of days during the 32-week study compared to 41% of days in patients on a standard-of-care augmentation therapyRead More | ATS: phase 2 data demonstrate the superiority of efdoralprin alfa over a standard-of-care augmentation therapy in achieving higher fAAT levels in AATD Data from the head-to-head study show efdoralprin alfaRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| John SmithCEO | Buy | 50,000 150,000 held | $45.50 | 01/10/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in SNY
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| KRENSAVAGE ASSET MANAGEMENT, LLC | 5.3 % (-13.1 %) | 13.82 M | 323.95 K |
SNY Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2027-12-17 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How SNY ranks across every disease it competes in
Competitive Position is a premium feature
See how SNY ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialSNY News
SNYSanofi and 2026 NBA Champion Karl-Anthony Towns team up to raise awareness of COVID-19 vaccination with NUVAXOVID®
Sanofi has partnered with NBA Champion Karl-Anthony Towns to promote COVID-19 vaccination awareness, particularly focusing on the NUVAXOVID vaccine. Towns will share his personal experiences with COVID-19 to encourage eligible individuals, especially those at higher risk, to discuss vaccination options with healthcare providers. The campaign aims to address vaccine hesitancy and improve vaccination rates.
Read more →SNYPress Release: Sanofi and Regeneron expand global Alliance with multiple next-generation, long-acting immunology antibodies
Sanofi and Regeneron have expanded their collaboration to include multiple next-generation, long-acting immunology antibodies. The agreement includes an upfront payment of $1 billion to Regeneron, with potential future milestone payments totaling up to $7 billion. The companies will co-develop and co-commercialize four new antibodies targeting interleukin pathways, enhancing their existing partnership established over 20 years.
Read more →SNYRegeneron and Sanofi Expand Global Alliance with Multiple Next-Generation, Long-Acting Immunology Antibodies
Regeneron and Sanofi have expanded their long-term collaboration by adding multiple next-generation antibodies, including REGN20423, a long-acting IL-13 monoclonal antibody. The agreement involves an upfront payment of $1 billion and potential milestone payments of up to $7 billion. This partnership aims to enhance the development of innovative therapies for type 2 inflammatory diseases, building on their successful history with Dupixent.
Read more →SNYSanofi inaugurates new flu vaccine facility, Canada's largest biomanufacturing investment
Sanofi has inaugurated the Charles Best Building, a new flu vaccine manufacturing facility in Toronto, marking a historic $925 million investment in Canadian biomanufacturing. This facility will produce the Fluzone High-Dose influenza vaccine and is set to create around 300 jobs. The investment aims to enhance Canada's pandemic preparedness and reinforce its position in the global life sciences sector.
Read more →SNYPress Release: Sanofi and Cheplapharm to create new strategic partnership in mature medicines
Sanofi and Cheplapharm announced a strategic partnership to transfer 20 mature medicines and three manufacturing sites. In exchange, Sanofi will acquire a 26.4% equity stake in Cheplapharm. This collaboration aims to tailor operations for mature medicines, ensuring they continue to meet patient needs while allowing Sanofi to focus on innovation. The transition is set to begin in early 2027.
Read more →SNYSanofi: Information concerning the total number of voting rights and shares - August 2026
Sanofi has released information regarding the total number of voting rights and shares as mandated by French regulations. The announcement includes details about the company's registered capital and its compliance with the French Commercial Code. This information is also accessible on Sanofi's official website.
Read more →SNYSanofi and Keke Palmer team up to urge parents to help protect babies from serious RSV with BEYFORTUS®
Sanofi has teamed up with actress Keke Palmer to promote awareness of RSV and the importance of immunization for infants. BEYFORTUS, a monoclonal antibody, is highlighted as a leading option for preventing serious RSV lung infections in babies. The campaign encourages parents to consult with healthcare providers about RSV protection ahead of the upcoming RSV season.
Read more →SNYSanofi: Information concerning the total number of voting rights and shares - July 2026
Sanofi has released information regarding the total number of voting rights and shares in compliance with French regulations. The company, registered in Paris, has a share capital of €2,415,546,786. This information is also accessible on Sanofi's official website for investors.
Read more →SNYPress Release: Sanofi’s MenQuadfi approved in the EU for use in infants from age six weeks against invasive meningococcal disease
Sanofi's MenQuadfi vaccine has received EU approval for use in infants starting from six weeks of age, expanding its previous indication for those aged 12 months and older. This decision follows a positive opinion from the Committee for Medicinal Products for Human Use and aims to enhance protection against invasive meningococcal disease. The vaccine's immunogenicity data supports its safety and efficacy for this younger demographic.
Read more →SNYCommuniqué de presse : Rapport financier semestriel 2026 de Sanofi
Sanofi has published its semi-annual financial report for the first half of 2026, which is now available to the public and has been submitted to the Autorité des marchés financiers (AMF). The report can be accessed on Sanofi's official website under the Investors section. The company emphasizes its commitment to innovation and improving lives through its research and development efforts.
Read more →SNYPress Release: Sanofi’s half-year financial report for 2026
Sanofi has released its half-year financial report for 2026, detailing its performance up to June 30. The report is accessible online and has been filed with regulatory bodies in France and the US. Sanofi emphasizes its commitment to research and development, focusing on improving healthcare through innovative solutions.
Read more →SNYPress Release: Sanofi announces decision not to submit amlitelimab in atopic dermatitis for global regulatory reviews
Sanofi has announced the discontinuation of clinical development for amlitelimab in atopic dermatitis, citing insufficient efficacy and safety evidence. Despite some positive findings in the ESTUARY phase 3 study, the drug was deemed not to offer significant improvements over current treatments. Sanofi will ensure a proper transition of care for patients involved in ongoing studies.
Read more →SNYPress Release: Sanofi evolves its Executive Committee to support its next strategic chapter
Sanofi has announced a restructuring of its Executive Committee to align with its strategic goals. The new committee will include key leaders across various functions, effective September 1, 2026. The changes are aimed at enhancing focus and execution in delivering on the company's priorities. Notably, some executives are transitioning to new roles, which may bring both opportunities and challenges.
Read more →SNYAqemia and Sanofi Expand Their Research Collaboration
Aqemia has announced the expansion of its research collaboration with Sanofi, which includes the nomination of a new therapeutic target and an additional payment. This collaboration, initially established in December 2023, allows Aqemia to potentially receive up to $140 million in total funding. The partnership emphasizes the integration of generative AI in drug discovery.
Read more →SNYSanofi: Information concerning the total number of voting rights and shares - June 2026
Sanofi has released information regarding the total number of voting rights and shares as required by French regulations. The announcement includes details about the company's registered share capital and its registered office. This information is accessible on Sanofi's official website for investors.
Read more →SNYPress Release: Sanofi’s subcutaneous Sarclisa Escena approved in the US as first anticancer treatment administered via on-body injector
Sanofi's Sarclisa Escena has received FDA approval as the first anticancer treatment to be administered via an on-body injector. This subcutaneous formulation is designed to enhance the treatment experience for patients with multiple myeloma, offering similar efficacy and safety as the intravenous version. The approval is based on the IRAKLIA phase 3 study, which showed comparable outcomes with a significantly reduced treatment time.
Read more →SNYPress Release: Sanofi’s Nexviazyme met all primary and secondary endpoints in infantile-onset Pompe disease phase 3 study
Sanofi's Nexviazyme successfully met all primary and secondary endpoints in the Baby-COMET phase 3 study for infantile-onset Pompe disease. The study demonstrated that treatment-naïve infants aged six months and younger were alive and free of invasive ventilation after 52 weeks. Sanofi plans to submit these results for regulatory approval in the US later in 2026.
Read more →SNYPress Release: Sanofi Foundation opens new chapter centered on future generations
The Sanofi Foundation is launching a new initiative focused on supporting children and young people, particularly those with serious health challenges. This includes partnerships aimed at improving early diagnosis and care for conditions like cerebral palsy. The Foundation is also committing €15 million annually to enhance its programs and humanitarian efforts, aiming to benefit over 6 million young individuals by 2030.
Read more →SNYDas Gesundheitsministerium und Sanofi gehen Partnerschaft ein, um Innovationen im Bereich der Impfstoffe voranzutreiben
The Department of Health in Abu Dhabi and Sanofi have signed a memorandum to enhance vaccine innovation through a partnership. This collaboration aims to establish a vaccine innovation center, leveraging AI and mRNA research to improve public health. The initiative is part of Abu Dhabi's commitment to global health security and aims to foster local scientific talent and advanced manufacturing.
Read more →SNYPress Release: Sanofi’s Wayrilz approved in Japan to treat immune thrombocytopenia
Sanofi's Wayrilz has been approved in Japan for the treatment of immune thrombocytopenia (ITP), based on positive results from the LUNA 3 phase 3 study. The drug, a BTK inhibitor, demonstrated significant improvements in platelet counts and other symptoms in patients. This approval offers a new therapeutic option for those who have not responded to existing treatments.
Read more →About Sanofi
BIOPHARMAWATCH ELITE PLUS
Trade the next SNY catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime